Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03955042 · ClinicalTrials.gov registry record · Phase 1
Pemetrexed for the Treatment of Chordoma
A Phase 1 study, sponsored by Saint John's Cancer Institute.
- Completed
- Registry status
- Phase 1
- Development phase
- 15
- Enrollment target
NCT03955042: Completed Phase 1 study, sponsored by Saint John's Cancer Institute.
NCT03955042 is a Phase 1 study that has completed, run by Saint John's Cancer Institute. The registered enrollment target is 15 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03955042, a Phase 1 study, has completed, sponsored by Saint John's Cancer Institute.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 15 participants
- Enrollment target
Study Summary
The purpose of this study is to test the safety and tolerability of pemetrexed administered to people with chordoma. Other purposes of this study are to: * find out side effects (good and bad) of pemetrexed; * learn more about how pemetrexed might affect the growth of cancer cells; * evaluate tumor characteristics by collecting tumor tissue samples if available; * look at biomarkers (biochemical features that can be used to measure the progress of disease or the effects of a drug) in blood and cerebrospinal fluid if available.
Primary Outcome
duration of time from start of treatment until objective tumor progression or withdrawal
Interventions
- DRUG Pemetrexed
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2019-09-06 |
| Est. Completion | 2023-01-18 |
| Phase | Phase 1 |
What the finished NCT03955042 record still lists
NCT03955042 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (75% lower).
The record links to 0 conditions, and to 1 intervention - of which Pemetrexed is the first listed.
NCT03955042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03955042 about?
NCT03955042 is a clinical study titled "Pemetrexed for the Treatment of Chordoma". The purpose of this study is to test the safety and tolerability of pemetrexed administered to people with chordoma. Other purposes of this study are to: * find out side effects (good and bad) of pemetrexed; * learn more about how pemetrexed might affect the growth of cancer cells; * evaluate tumor...
What is the current status of trial NCT03955042?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 15 participants. The study started on 2019-09-06. Estimated completion is 2023-01-18.
What interventions are being tested in trial NCT03955042?
The interventions under investigation include: Pemetrexed (DRUG).
Who is sponsoring clinical trial NCT03955042?
This trial is sponsored by Saint John's Cancer Institute, which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03955042's enrollment target sits among peer trials
15 1798th of 2000 higher than 157 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI